Know Labs, Inc.

Know Labs, Inc.

KNWN
Know Labs, Inc.US flagOther OTC
3.55
USD
+0.40
- -
398.82MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
18.13
10.46
7.2
5.56
4.22
1.27
0.5
0.1
0.01
- -
0.11
- -
- -
- -
Basic EPS, GAAP
-6.25
-8.08
-0.92
-2.33
-1.22
-1.01
-0.38
-0.42
-0.62
-0.86
-0.5
-0.41
-0.2
-0.2
Free Cash Flow per Basic Share
-0.13
-4.27
-1.24
-0.21
-1.92
-0.33
-0.14
-0.18
-0.18
-0.24
-0.19
-0.21
-0.15
-0.13
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-31.63
-24.86
-19.42
-21.35
-18.95
-8.2
-4.03
-2.35
-2.57
-2.77
-2.51
-2.46
-1.61
-1.57
Tangible Book Value per Share
-4.33
-5.51
-4.35
-5.76
-2.69
-1.03
-0.35
-0.2
-0.09
0.04
0.24
0.08
-0.03
-0.04
Basic Weighted Avg Shares
- -
1
1
1
1
4
9
18
22
29
40
50
86
91
Sales/Revenue/Turnover
8
9
8
6
6
5
4
2
- -
- -
4
- -
- -
- -
Operating Margin (%)
-28.04
-45.43
-32.08
-37.04
-44.71
-46.36
-52.47
-277.74
-5,597.82
- -
-288.39
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-3
-7
-1
-3
-2
-4
-3
-8
-14
-25
-20
-15
-17
-18
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-34.48
-77.24
-12.74
-41.82
-28.99
-80.04
-75.7
-421.74
-11,122.48
- -
-460.34
- -
- -
- -
Working Capital
-2
-5
-5
-7
-4
-4
-3
-4
-2
1
9
4
-2
-4
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
1
- -
Total Equity
- -
-3
-3
-5
-3
-4
-3
-3
-2
1
10
4
-2
-4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Jun'24
Sep'24
Dec'25
ST Debt
5
4
4
LT Borrowings
1
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
86
108
111
Market Capitalization
1,344
939
627

Working Capital

FRC

in mil. unless spec.
Jun'24
Sep'24
Dec'25
Total Current Assets
2
3
1
Cash, Cash Equivalents & STI
2
3
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
5
5
Payables & Accruals
1
1
1
ST Debt
5
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
31.09%
53.51%
-157.59%
Free Cash Flow
123.77%
34.22%
23.58%
Net Income, GAAP
49.45%
25.78%
8.45%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
-93.92%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.08
-0.1
-0.18
- -
-0.41
2024
-0.04
-0.07
-0.05
- -
-0.2
2025
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Ronald P. Erickson
Full Time Employees
7
Sector
Technology
Industry
Hardware, Equipment & Parts
Address
500 Union Street Seattle WA United States of America 98101
IPO Date
Apr 18, 2006
Business
Know Labs, Inc. (NYSE American: KNW) develops and commercializes proprietary non-invasive medical diagnostic technologies based on radiofrequency (RF) dielectric spectroscopy and Bio-RFID platforms that use radio waves and electromagnetic energy to identify, measure, and analyze molecular signatures of organic and inorganic materials in real-time; its core products include the KnowU wearable continuous glucose monitor (CGM) for pain-free blood glucose tracking via adhesive or strap attachment, a companion mobile app for real-time readings and trend analysis, and a form-factor-agnostic technology applicable to over 100 diagnostic uses such as oxygen, alcohol, and metabolized drugs, with potential extensions to industrial sectors like food, agriculture, and security. Founded in 1998 and headquartered in Seattle, Washington, the company targets diabetes management for over 550 million global patients with Type 1 and Type 2 diabetes plus prediabetes, alongside broader health monitoring markets, while operating principally in the United States through medical-grade devices advancing toward FDA clearance via ongoing clinical trials, hardware development, algorithm refinement, and a portfolio of more than 270 patents worldwide. In August 2025, Goldeneye 1995 LLC, an affiliate of fintech investor Greg Kidd, completed a $125 million strategic acquisition of controlling interest through 1,000 Bitcoin and $15 million cash contributions for 357.8 million new shares, triggering leadership changes with Kidd assuming roles as chief executive officer and chairman, new executives including Kirk Chapman as COO and Kitty Payne as CFO, founder Ron Erickson transitioning to president of a retained diagnostics division and lead director, a corporate rebranding to USBC, Inc. with ticker change to USBC effective August 15, 2025, and a pivot to multi-disciplinary operations incorporating Bitcoin yield-generation treasury strategies, USBC token development as a redeemable high-yield digital dollar on blockchain with digital identity features, and sustained investment in non-invasive health innovations.

Company News

APIChatGPT
  • Know Labs Technology Licensing (KTL) Announces Formalized Client Engagement

  • Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Driving

  • Why Is Know Labs (KNW) Stock Down 37% Today?

  • Know Labs Seeks $6 Million In Uplisting IPO To Nasdaq